<< Back to News

FDA Approves Celgene's IDHIFA®

Celgene Corporation is pleased to announce that IDHIFA is now approved and available for adult patients with relapsed or refractory (R/R) AML and an IDH2 mutation.

Links:

Approval Announcement of IDHIFA

Prescribing Information